1-3 of 3
Thierry J Horner, PhD
Close
Sort by
Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose
Journal: Blood
Blood (2010) 116 (21): 3960.
https://doi.org/10.1182/blood.V116.21.3960.3960
Published: 2010
Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC
Journal: Blood
Blood (2010) 116 (21): 4916.
https://doi.org/10.1182/blood.V116.21.4916.4916
Published: 2010
Journal Articles

Tositumomab and Iodine I-131 Tositumomab (Bexxar® therapeutic regimen) for Non-Hodgkin's Lymphoma Patients Who Progressed After Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study.

Sandra J Horning, MD, Anas Younes, MD, Donald Podoloff, MD, Thierry J Horner, PhD, Vanessa C Williams, MS, Christina Vleisides, Michael Goris, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2732.
https://doi.org/10.1182/blood.V114.22.2732.2732
Published: 2009